These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 26009617)

  • 41. [Resistance to antitubercular drugs in patients with tuberculosis registered in the antituberculosis clinics in Poland 1966-1980].
    Szczuka I
    Pneumonol Pol; 1982 Oct; 50(10):497-501. PubMed ID: 6820494
    [No Abstract]   [Full Text] [Related]  

  • 42. Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
    Kigondu EM; Wasuna A; Warner DF; Chibale K
    Bioorg Med Chem; 2014 Aug; 22(16):4453-61. PubMed ID: 24997576
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis.
    Byrne ST; Denkin SM; Zhang Y
    J Antimicrob Chemother; 2007 Feb; 59(2):313-6. PubMed ID: 17185297
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rising standards for tuberculosis drug development.
    Balganesh TS; Alzari PM; Cole ST
    Trends Pharmacol Sci; 2008 Nov; 29(11):576-81. PubMed ID: 18799223
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oral poly(lactide-co-glycolide) nanoparticle based antituberculosis drug delivery: toxicological and chemotherapeutic implications.
    Pandey R; Sharma S; Khuller GK
    Indian J Exp Biol; 2006 Jun; 44(6):459-67. PubMed ID: 16784116
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A roadmap for drug discovery and its translation to small molecule agents in clinical development for tuberculosis treatment.
    Showalter HD; Denny WA
    Tuberculosis (Edinb); 2008 Aug; 88 Suppl 1():S3-17. PubMed ID: 18762151
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro activities of the newly synthesised ER-2 against clinical isolates of Mycobacterium tuberculosis susceptible or resistant to antituberculosis drugs.
    Rao SS; Raghunathan R; Ekambaram R; Raghunathan M
    Int J Antimicrob Agents; 2009 Nov; 34(5):451-3. PubMed ID: 19625168
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.
    Andries K; Verhasselt P; Guillemont J; Göhlmann HW; Neefs JM; Winkler H; Van Gestel J; Timmerman P; Zhu M; Lee E; Williams P; de Chaffoy D; Huitric E; Hoffner S; Cambau E; Truffot-Pernot C; Lounis N; Jarlier V
    Science; 2005 Jan; 307(5707):223-7. PubMed ID: 15591164
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacologic considerations in use and development of antituberculosis drugs.
    Davies G
    Cold Spring Harb Perspect Med; 2014 Sep; 5(1):a021170. PubMed ID: 25237145
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Primary resistance to antituberculosis drugs: a national survey conducted in Côte d'Ivoire in 1995-1996. Ivoirian Study Group on Tuberculosis Resistance.
    Dosso M; Bonard D; Msellati P; Bamba A; Doulhourou C; Vincent V; Peyre M; Traore M; Koffi K; Coulibaly IM
    Int J Tuberc Lung Dis; 1999 Sep; 3(9):805-9. PubMed ID: 10488889
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
    Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
    Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Drug-resistant tuberculosis: controversies and challenges in pediatrics.
    Smith KC; Seaworth BJ
    Expert Rev Anti Infect Ther; 2005 Dec; 3(6):995-1010. PubMed ID: 16307511
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Model-Based Meta-Analysis of Relapsing Mouse Model Studies from the Critical Path to Tuberculosis Drug Regimens Initiative Database.
    Berg A; Clary J; Hanna D; Nuermberger E; Lenaerts A; Ammerman N; Ramey M; Hartley D; Hermann D
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0179321. PubMed ID: 35099274
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapeutic drug monitoring in antituberculosis chemotherapy: clinical perspectives.
    Yew WW
    Clin Chim Acta; 2001 Nov; 313(1-2):31-6. PubMed ID: 11694236
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Quantitative assessment of the activity of antituberculosis drugs and regimens.
    Chirehwa MT; Velásquez GE; Gumbo T; McIlleron H
    Expert Rev Anti Infect Ther; 2019 Jun; 17(6):449-457. PubMed ID: 31144539
    [No Abstract]   [Full Text] [Related]  

  • 56. Resistance to antituberculosis drugs.
    Wkly Epidemiol Rec; 2000 May; 75(19):156-9. PubMed ID: 10850223
    [No Abstract]   [Full Text] [Related]  

  • 57. Comparisons of Analysis Methods for Assessment of Pharmacodynamic Interactions Including Design Recommendations.
    Chen C; Wicha SG; Nordgren R; Simonsson USH
    AAPS J; 2018 Jun; 20(4):77. PubMed ID: 29931471
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Systematic measurement of combination-drug landscapes to predict in vivo treatment outcomes for tuberculosis.
    Larkins-Ford J; Greenstein T; Van N; Degefu YN; Olson MC; Sokolov A; Aldridge BB
    Cell Syst; 2021 Nov; 12(11):1046-1063.e7. PubMed ID: 34469743
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Transcriptomics: the key to biomarker discovery during tuberculosis?
    van Rensburg IC; Loxton AG
    Biomark Med; 2015; 9(5):483-95. PubMed ID: 25985177
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tuberculosis chemotherapy. The need for new antituberculosis drugs is urgent.
    Bates JH
    Am J Respir Crit Care Med; 1995 Apr; 151(4):942-3. PubMed ID: 7697270
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.